Parallax Volatility Advisers
TCRT icon

Parallax Volatility Advisers’s Alaunos Therapeutics TCRT Stock Holding History

Parallax Volatility Advisers’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13
Closed -$3K – 3253
2022
Q3 		$3K Buy
+13
New +$3.78K ﹤0.01% 2947
2018
Q2 		– Sell
-102
Closed -$60K – 3259
2018
Q1 		$60K Sell
102
-133
-57% -$82.9K ﹤0.01% 1473
2017
Q4 		$146K Buy
+235
New +$169K ﹤0.01% 2528

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Parallax Volatility Advisers's TCRT Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 13 shares — an estimated $3K sold.

Parallax Volatility Advisers first reported a position in TCRT in Q4 2017 and held it in 3 quarters. The position peaked at $146K in Q4 2017. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 13 Alaunos Therapeutics shares in Q4 2022, an estimated $3K.
  • Parallax Volatility Advisers first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 3 quarters.
  • Parallax Volatility Advisers's Alaunos Therapeutics position peaked at $146K in Q4 2017.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.